BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,839,976 | +0.6% | 1,672,313 | 0.0% | 0.02% | 0.0% |
| Q2 2023 | $11,773,084 | +11.3% | 1,672,313 | +31.8% | 0.02% | -8.7% |
| Q1 2023 | $10,582,226 | -38.0% | 1,268,852 | -14.6% | 0.02% | -65.2% |
| Q4 2022 | $17,057,179 | -7.6% | 1,485,817 | +1.4% | 0.07% | +10.0% |
| Q3 2022 | $18,463,000 | +49.4% | 1,465,285 | +25.4% | 0.06% | +81.8% |
| Q2 2022 | $12,361,000 | -36.0% | 1,168,345 | -1.6% | 0.03% | -15.4% |
| Q1 2022 | $19,314,000 | – | 1,187,845 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 3,926,700 | $56,427,000 | 4.43% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $27,601,000 | 3.44% |
| HealthCor Management, L.P. | 3,849,470 | $55,317,000 | 2.39% |
| MPM BioImpact LLC | 704,767 | $10,128,000 | 1.57% |
| Baker Brothers Advisors | 12,710,818 | $182,654,000 | 0.80% |
| Bain Capital Public Equity Management II, LLC | 1,472,471 | $21,159,000 | 0.74% |
| Biondo Investment Advisors, LLC | 267,480 | $3,844,000 | 0.66% |
| North Star Investment Management Corp. | 442,900 | $6,364,000 | 0.52% |
| DOLIVER ADVISORS, LP | 100,000 | $1,437,000 | 0.48% |
| Lisanti Capital Growth, LLC | 219,450 | $3,153,000 | 0.46% |